Mitch Shultz

3 weeks ago | optometrytimes.com | Mitch Shultz |Emily Kaiser Maharjan

June 6, 2025By At the 2025 ASCRS meeting, Mitch Shultz, MD, presented compelling new findings from a 12-week clinical trial investigating the impact of lotilaner 0.25% ophthalmic solution on meibomian gland function. At the 2025 ASCRS meeting, Mitch Shultz, MD, an anterior segment surgeon based in Los Angeles, presented compelling new findings from a 12-week clinical trial investigating the impact of lotilaner 0.25% ophthalmic solution on patients with Demodex blepharitis.